Meparfynol is a tertiary hexanol and potent tranquilizer with hypnotic/sedative and anticonvulsant effects and exceptionally low therapeutic index. It was discovered by Bayer in 1913 and was used shortly thereafter for the treatment of insomnia, but its use was quickly phased out in response to newer drugs with far more favorable safety profiles. Meparfynol depresses monosynaptic and polysynaptic reflexes and exerted weak ganglion and neuromuscular blocking actions. Meparfynol also produces transitory hypotension, an increase of aortic blood flow. Perfusion of the coronary arteries with Meparfynol led to a slowing of the heart, diminished systolic amplitude, dysrhythmias, and increased coronary flow. Respiration was stimulated with small and depressed with larger doses of Meparfynol.

Chlorphenesin is a preservative and cosmetic biocide that helps prevent the growth of microorganisms. In cosmetics and personal care products, Chlorphenesin is used in the formulation of aftershave lotions, bath products, cleansing products, deodorants, hair conditioners, makeup, skin care products, personal cleanliness products, and shampoos. Chlorphenesin has been reported to cause irritation and contact dermatitis in some people, particularly those with sensitive and dry skin. The Cosmetic Ingredient Review (CIR) expert panel released a safety assessment in October 2012, however, that stated chlorphenesin at 0.3 percent (as it exists in personal care products) was classified as having “negligible dermal irritation potential.”